Glucose Fresenius

Glucose Fresenius is an intravenous solution for injection that contains glucose monohydrate as its active ingredient; the product is supplied in a standard concentration (strength not specified) and is marketed in the European Union as a prescription‑only nutritional supplement used to provide carbohydrate calories and raise blood glucose levels. It is administered by healthcare professionals under controlled conditions and is classified as an excipient/solvent within the ATC group A12BA01.

Glucose Fresenius is indicated for several clinical situations where rapid carbohydrate delivery or fluid replacement is required.

- Treatment of acute hypoglycemia in emergency settings. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Support of fluid and electrolyte balance during peri‑operative care. - Provision of caloric substrate in critical‑care or pediatric patients. - Management of electrolyte disturbances associated with glucose infusion.

When administered intravenously, Glucose Fresenius may be associated with a range of observed effects, most of which are related to its carbohydrate load and infusion characteristics.

Common: - Transient hyperglycemia or elevated blood glucose readings. - Local irritation or phlebitis at the infusion site. - Mild nausea or vomiting. - Electrolyte shifts such as mild hypokalemia.

Serious: - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis. - Anaphylactic or severe allergic reaction. - Fluid overload causing pulmonary edema or cardiac strain.

Clinicians should observe several precautions before and during the use of Glucose Fresenius to minimize risks.

- Verify blood glucose level and adjust infusion rate in diabetic or hyperglycemic patients. - Assess fluid status to avoid overload in patients with heart or renal failure. - Monitor electrolytes, especially potassium and sodium, during prolonged infusion. - Use aseptic technique and inspect solution for particulates before administration. - Consider pregnancy status; safety data are limited. - Store according to manufacturer guidelines to maintain solution stability.

Glucose Fresenius can interact with other medications or solutions administered intravenously; awareness of these interactions helps ensure safe therapy.

Avoid: - Co‑administration with high‑dose insulin or other potent hypoglycemic agents without glucose monitoring. - Simultaneous infusion of potassium‑containing solutions that may precipitate with calcium.

Use with caution: - Concurrent use of diuretics that affect fluid and electrolyte balance. - Beta‑blockers or catecholamines that may mask hypoglycemia symptoms. - Corticosteroids that increase glucose production. - Other carbohydrate‑containing IV fluids that could raise total caloric load.